DXCM•Analysts have ranked DexCom among the 52 S&P 500 companies with a consensus Strong Buy score below 2.5, reflecting bullish sentiment from industry surveys. This designation follows a two-month rally off March lows and rising forward earnings estimates that have improved valuations.
A recent industry analysts’ survey placed DexCom among 52 S&P 500 names with a consensus recommendation score below 2.5, the threshold for a Strong Buy rating. This marks DexCom as a top-rated stock within the index’s coverage universe.
DexCom’s Strong Buy designation follows a two-month rally that lifted the S&P 500 off its late-March lows. Rising forward earnings estimates across the index have bolstered valuations, supporting bullish sentiment in select healthcare and technology stocks, including DexCom.
